http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-105848-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fda45c540f11df3a7fe71d54a70562a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2016-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-105848-A1 |
| titleOfInvention | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES |
| abstract | Claim 1: A compound of the formula (1) wherein: V represents O or S; R² and R³ independently represent hydrogen or fluorine; and M is one of the groups of formula (2) and (3), where in the group of formula (2): A represents a bond or -C ° C; R¹A represents hydrogen, or halogen; R²A represents hydrogen, or halogen; and R³A represents C₁₋₃alkoxy; hydroxy-C₁₋₄alkyl; or RNA¹RNA²N-C₁₋₃alkyl, where RNA¹ and RNA² independently represent hydrogen or C₁₋₃alkyl; or RNA¹ and RNA² together with the nitrogen to which they are attached form a 4 to 6-membered saturated ring that optionally contains an oxygen ring atom, where said ring is unsubstituted, or fluorinated monosubstituted; and where in the group of formula (3): R¹B represents hydroxy-C₁₋₄alkyl; 1- (3-hydroxyazetidine) -1-carbonyloxymethyl; 1-hydroxymethyl-cycloprop-1-yl, or a group that is one of its prodrugs, wherein said group is 1 - ((phosphonooxy) methyl) -cycloprop-1-yl, 1 - [(di (C₁₋₄alkylamino) - C₁₋₃alkyl-carbonyloxymethyl] -cycloprop-1-yl, 1 - {[(2- (phosphonooxy-C₁₋₄alkyl) -phenyl) -C₁₋₄alkyl] -carbonyloxymethyl} -cycloprop-1-yl, 1 - {[2 - (phosphonooxy-C₁₋₄alkyl) -phenyl] -carbonyloxymethyl} -cycloprop-1-yl, or 1 - {[(2-phosphonooxy-phenyl) -C₁₋₄alkyl] -carbonyloxymethyl} -cycloprop-1-yl; trans- 2-hydroxymethyl-cycloprop-1-yl, or a group that is one of its prodrugs where said group is trans-2- (phosphonooxymethyl) -cycloprop-1-yl, trans-2 - [(diC₁₋₄alkyloamino) -C₁₋ ₃alkyl-carbonyloxymethyl] -cycloprop-1-yl, trans-2 - {[(2- (phosphonooxy-C₁₋₄alkyl) -phenyl) -C₁₋₄alkyl] -carbonyloxymethyl} -cycloprop-1-yl, trans-2- { [2- (phosphonooxy-C₁₋₄alkyl) -phenyl] -carbonyloxymethyl} -cycloprop-1-yl, or trans-2 - {[(2-phosphonoxy-phenyl) -C₁₋₄alkyl] -carbonyloxymethyl} -cycloprop-1- ilo; 2-fl úor-2-hydroxymethyl-cycloprop-1-yl, or a group that is one of its prodrugs, where said group is 2-fluorine-2- (phosphonooxymethyl) -cycloprop-1-yl, 2-fluorine-2 - [( diC₁₋₄alkyloamino) -C₁₋₃alkylcarbonyloxymethyl] -cycloprop-1-yl, 2-fluorine-2 - {[(2- (phosphonooxy-C₁₋₄alkyl) -phenyl) -C₁₋₄alkyl] -carbonyloxymethyl} -cycloprop- 1-yl, 2-fluorine-2 - {[2- (phosphonooxy-C₁₋₄alkyl) -phenyl] -carbonyloxymethyl} -cycloprop-1-yl, or 2-fluorine-2 - {[(2-phosphonooxy-phenyl) -C₁₋₄alkyl] -carbonyloxymethyl} -cycloprop-1-yl; 3-hydroxy-oxetan-3-yl; trans-2- (1,2-dihydroxyethyl) cycloprop-1-yl; trans- (cis-3,4-dihydroxy) -cyclopent-1-yl; RNB¹RNB²N-C₁₋₃alkyl, where RNB¹ and RNB² independently represent hydrogen or C₁₋₃alkyl; 1- (RNB³RNB⁴N) -cycloprop-1-yl, where RNB³ and RNB⁴ independently represent hydrogen or C₁₋₃alkyl, or RNB³ represents hydrogen and RNB⁴, (phosphonooxy) methoxycarbonyl; azetidin-3-yl, wherein said azetidin-3-yl is unsubstituted, or mono- or di-substituted, where, if present, a substituent binds at position 1 of said azetidin-3-yl group, wherein said substituent is selected from C₁₋₃alkyl, C₃₋₄cycloalkyl, oxetan-3-yl, w-fluorine-C₂alkyl, or w-hydroxy-C₂₋₄alkyl; and / or a substituent is fluorine attached at position 3 of said azetidin-3-yl group; R¹ represents hydrogen, or R¹ represents -PO₃H₂, -SO₃H, phosphonooxymethyl, or the group L represented by the formula (4), where R⁴ represents C₁₋₄alkyloaminoC₁₋₄alkyl, diC₁₋₄alkyloaminoC₁₋₄alkyl, phosphonooxyC₁₋₄alkyl, phosphonooxymethoxy, 2- (phosphonooxy-C₁₋₄alkyl) -phenyl, [2- (phosphonooxy-C₁₋₄alkyl) -phenyl] -C₁₋₄alkyl, or (2- (phosphonooxy) -phenyl) -C₁₋₄alkyl; or one of its pharmaceutically acceptable salts. |
| priorityDate | 2015-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.